Calcificazioni cardiovascolari e aterosclerosi accelerata in corso di uremia

Translated title of the contribution: Cardiovascular calcification and atherosclerosis accelerated during uremia

Mario Cozzolino, Alessandra Butti, Giusy Chiarelli, Lisa Rocca-Rey, Gaia Santagostino, Maurizio Gallieni, Diego Brancaccio

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cardiovascular disease is the first cause of morbidity and mortality in dialysis patients. Hyperphosphatemia and elevated serum calcium-phosphate levels have recently been investigated as inducing factors on extraskeletal calcification in this population. In vitro studies demonstrated that human aortic smooth muscle cells calcify when incubated in a high phosphate medium, where calcium and calcitriol are not changed. Furthermore, the lack of inhibitory proteins, such as fetuin and matrix Gla protein, is a possible main determinant of calcium-phosphate deposition in soft tissues. The classical treatment of hyperphosphatemia and secondary hyperparathyroidism in dialysis patients consists of calcium-based phosphate binders and calcitriol administration. Unfortunately, this "first-generation" therapy is not free of dramatic side effects. New free-calcium and -aluminum phosphate binders, new vitamin D metabolites, and calcimimetics are examples of "second-generation" therapies that may prevent vascular calcification and possibly prevent some of the burden of cardiovascular disease in uremia.

Original languageItalian
Pages (from-to)25-28
Number of pages4
JournalItalian Heart Journal Supplement
Volume6
Issue number1
Publication statusPublished - Jan 2005

Fingerprint

Uremia
Atherosclerosis
Hyperphosphatemia
Calcitriol
Dialysis
Cardiovascular Diseases
Fetuins
Vascular Calcification
Secondary Hyperparathyroidism
Vitamin D
Smooth Muscle Myocytes
Therapeutics
Morbidity
Mortality
calcium phosphate
Serum
Population
Proteins

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cozzolino, M., Butti, A., Chiarelli, G., Rocca-Rey, L., Santagostino, G., Gallieni, M., & Brancaccio, D. (2005). Calcificazioni cardiovascolari e aterosclerosi accelerata in corso di uremia. Italian Heart Journal Supplement, 6(1), 25-28.

Calcificazioni cardiovascolari e aterosclerosi accelerata in corso di uremia. / Cozzolino, Mario; Butti, Alessandra; Chiarelli, Giusy; Rocca-Rey, Lisa; Santagostino, Gaia; Gallieni, Maurizio; Brancaccio, Diego.

In: Italian Heart Journal Supplement, Vol. 6, No. 1, 01.2005, p. 25-28.

Research output: Contribution to journalArticle

Cozzolino, M, Butti, A, Chiarelli, G, Rocca-Rey, L, Santagostino, G, Gallieni, M & Brancaccio, D 2005, 'Calcificazioni cardiovascolari e aterosclerosi accelerata in corso di uremia', Italian Heart Journal Supplement, vol. 6, no. 1, pp. 25-28.
Cozzolino M, Butti A, Chiarelli G, Rocca-Rey L, Santagostino G, Gallieni M et al. Calcificazioni cardiovascolari e aterosclerosi accelerata in corso di uremia. Italian Heart Journal Supplement. 2005 Jan;6(1):25-28.
Cozzolino, Mario ; Butti, Alessandra ; Chiarelli, Giusy ; Rocca-Rey, Lisa ; Santagostino, Gaia ; Gallieni, Maurizio ; Brancaccio, Diego. / Calcificazioni cardiovascolari e aterosclerosi accelerata in corso di uremia. In: Italian Heart Journal Supplement. 2005 ; Vol. 6, No. 1. pp. 25-28.
@article{47c19aee1bf6473b9b566cfca707a5d8,
title = "Calcificazioni cardiovascolari e aterosclerosi accelerata in corso di uremia",
abstract = "Cardiovascular disease is the first cause of morbidity and mortality in dialysis patients. Hyperphosphatemia and elevated serum calcium-phosphate levels have recently been investigated as inducing factors on extraskeletal calcification in this population. In vitro studies demonstrated that human aortic smooth muscle cells calcify when incubated in a high phosphate medium, where calcium and calcitriol are not changed. Furthermore, the lack of inhibitory proteins, such as fetuin and matrix Gla protein, is a possible main determinant of calcium-phosphate deposition in soft tissues. The classical treatment of hyperphosphatemia and secondary hyperparathyroidism in dialysis patients consists of calcium-based phosphate binders and calcitriol administration. Unfortunately, this {"}first-generation{"} therapy is not free of dramatic side effects. New free-calcium and -aluminum phosphate binders, new vitamin D metabolites, and calcimimetics are examples of {"}second-generation{"} therapies that may prevent vascular calcification and possibly prevent some of the burden of cardiovascular disease in uremia.",
keywords = "Calcification, Calcium, Kidney, Phosphates",
author = "Mario Cozzolino and Alessandra Butti and Giusy Chiarelli and Lisa Rocca-Rey and Gaia Santagostino and Maurizio Gallieni and Diego Brancaccio",
year = "2005",
month = "1",
language = "Italian",
volume = "6",
pages = "25--28",
journal = "Italian Heart Journal Supplement",
issn = "1129-4728",
publisher = "Centro Editoriale Pubblicitario Italiano",
number = "1",

}

TY - JOUR

T1 - Calcificazioni cardiovascolari e aterosclerosi accelerata in corso di uremia

AU - Cozzolino, Mario

AU - Butti, Alessandra

AU - Chiarelli, Giusy

AU - Rocca-Rey, Lisa

AU - Santagostino, Gaia

AU - Gallieni, Maurizio

AU - Brancaccio, Diego

PY - 2005/1

Y1 - 2005/1

N2 - Cardiovascular disease is the first cause of morbidity and mortality in dialysis patients. Hyperphosphatemia and elevated serum calcium-phosphate levels have recently been investigated as inducing factors on extraskeletal calcification in this population. In vitro studies demonstrated that human aortic smooth muscle cells calcify when incubated in a high phosphate medium, where calcium and calcitriol are not changed. Furthermore, the lack of inhibitory proteins, such as fetuin and matrix Gla protein, is a possible main determinant of calcium-phosphate deposition in soft tissues. The classical treatment of hyperphosphatemia and secondary hyperparathyroidism in dialysis patients consists of calcium-based phosphate binders and calcitriol administration. Unfortunately, this "first-generation" therapy is not free of dramatic side effects. New free-calcium and -aluminum phosphate binders, new vitamin D metabolites, and calcimimetics are examples of "second-generation" therapies that may prevent vascular calcification and possibly prevent some of the burden of cardiovascular disease in uremia.

AB - Cardiovascular disease is the first cause of morbidity and mortality in dialysis patients. Hyperphosphatemia and elevated serum calcium-phosphate levels have recently been investigated as inducing factors on extraskeletal calcification in this population. In vitro studies demonstrated that human aortic smooth muscle cells calcify when incubated in a high phosphate medium, where calcium and calcitriol are not changed. Furthermore, the lack of inhibitory proteins, such as fetuin and matrix Gla protein, is a possible main determinant of calcium-phosphate deposition in soft tissues. The classical treatment of hyperphosphatemia and secondary hyperparathyroidism in dialysis patients consists of calcium-based phosphate binders and calcitriol administration. Unfortunately, this "first-generation" therapy is not free of dramatic side effects. New free-calcium and -aluminum phosphate binders, new vitamin D metabolites, and calcimimetics are examples of "second-generation" therapies that may prevent vascular calcification and possibly prevent some of the burden of cardiovascular disease in uremia.

KW - Calcification

KW - Calcium

KW - Kidney

KW - Phosphates

UR - http://www.scopus.com/inward/record.url?scp=15944386326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15944386326&partnerID=8YFLogxK

M3 - Articolo

VL - 6

SP - 25

EP - 28

JO - Italian Heart Journal Supplement

JF - Italian Heart Journal Supplement

SN - 1129-4728

IS - 1

ER -